Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

10 Feb 2010

APA releases proposed draft diagnostic criteria for DSM-5

The American Psychiatric Association today released the proposed draft diagnostic criteria for the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM). The draft criteria represent content changes under consideration for DSM, which is the standard classification of mental disorders used by mental health and other health professionals, and is used for diagnostic and research purposes.

10 Feb 2010

Gene linked to PMDD and other maladies during menstrual cycle

Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.

9 Feb 2010

Scientists still searching for valid biomarker for schizophrenia and bipolar disorder

Schizophrenia and bipolar disorder affect tens of millions of individuals around the world. These disorders have a typical onset in the early twenties and in most cases have a chronic or recurring course.

4 Feb 2010

Neuroscience research and clinical care launched at UT Medical School

Innovative neuroscience research and expanded clinical care have been launched at the new Center of Excellence on Mood Disorders at The University of Texas Medical School at Houston.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

Study: Schizophrenia patients may experience beneficial brain changes in response to exercise

Potentially beneficial brain changes (an increase in the volume of an area known as the hippocampus) occur in response to exercise both in patients with schizophrenia and healthy controls, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

1 Feb 2010

Majority of doctors appear to ignore FDA warning to screen high-risk medications

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

13 Jan 2010

Prescribing culture of antipsychotic medications in nursing homes examined

Older adults newly admitted to nursing homes with high rates of antipsychotic prescribing in the previous year are more likely to receive antipsychotic agents, according to a report in the January 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Of these treated patients, some had no identified clinical indication for this therapy.

12 Jan 2010

Perturbing DISC1 gene could help researchers treat mental illness, says study

Scientists have long eyed mutations in a gene known as DISC1 as a possible contributor to schizophrenia and mood disorders, including depression and bipolar disorder. Now, new research led by Johns Hopkins researchers suggests that perturbing this gene during prenatal periods, postnatal periods or both may have different effects in mice, leading to separate types of brain alterations and behaviors with resemblance to schizophrenia or mood disorders.

6 Jan 2010

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

3 Jan 2010

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA).

15 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Antiepileptic drugs may have a possible protective effect against seizure disorders

Despite government warnings about an increased risk of suicidal thoughts and actions while taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in individuals with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Two Brown University faculty members receive federal funding for new neuroscience research projects

Two Brown University faculty members have received federal funding for innovative new neuroscience research projects focusing on brain development in infants and bipolar disorder in children.

7 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

APA releases proposed draft diagnostic criteria for DSM-5

Gene linked to PMDD and other maladies during menstrual cycle

Scientists still searching for valid biomarker for schizophrenia and bipolar disorder

Neuroscience research and clinical care launched at UT Medical School

Study shows Cymbalta reduces chronic low back pain

Study: Schizophrenia patients may experience beneficial brain changes in response to exercise

Majority of doctors appear to ignore FDA warning to screen high-risk medications

Prescribing culture of antipsychotic medications in nursing homes examined

Perturbing DISC1 gene could help researchers treat mental illness, says study

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Antiepileptic drugs may have a possible protective effect against seizure disorders

Two Brown University faculty members receive federal funding for new neuroscience research projects

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Eli Lilly's Cymbalta receives FDA approval

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in